Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer ; volume:130 ; number:6 ; day:20 ; month:1 ; year:2024 ; pages:941-950 ; date:4.2024
British journal of cancer ; 130, Heft 6 (20.1.2024), 941-950, 4.2024
- Creator
-
Nicum, Shibani
McGregor, Naomi
Austin, Rachel
Collins, Linda
Dutton, Susan
McNeish, Iain
Glasspool, Rosalind
Hall, Marcia
Roux, Rene
Michael, Agnieszka
Clamp, Andrew
Jayson, Gordon
Kristeleit, Rebecca
Banerjee, Susana
Mansouri, Anita
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-023-02567-6
- URN
-
urn:nbn:de:101:1-2405211145539.004321795348
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nicum, Shibani
- McGregor, Naomi
- Austin, Rachel
- Collins, Linda
- Dutton, Susan
- McNeish, Iain
- Glasspool, Rosalind
- Hall, Marcia
- Roux, Rene
- Michael, Agnieszka
- Clamp, Andrew
- Jayson, Gordon
- Kristeleit, Rebecca
- Banerjee, Susana
- Mansouri, Anita
- SpringerLink (Online service)
Other Objects (12)
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Olaparib (Mammakarzinom) : Addendum zum Auftrag A19-57
Olaparib (Prostatakarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib (Pankreaskarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib (Prostatakarzinom) : Addendum zum Auftrag A20-106
Olaparib (Mammakarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Olaparib (Mammakarzinom) : Addendum zum Auftrag A19-57
Olaparib (Prostatakarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib (Pankreaskarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib (Prostatakarzinom) : Addendum zum Auftrag A20-106
Olaparib (Mammakarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Olaparib (Mammakarzinom) : Addendum zum Auftrag A19-57
Olaparib (Prostatakarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib (Pankreaskarzinom) : Nutzenbewertung gemäß § 35a SGB V
Olaparib (Prostatakarzinom) : Addendum zum Auftrag A20-106